Ko-Med Centra Kliniczne Sp. z o.o.

Lublin 15 trials 1 recruiting

15 Registered trials

1 Currently recruiting

Organisation

Ko-Med Centra Kliniczne Sp. z o.o.

Location

Lublin, Poland

Identifier

ORG-100039546

Address

Ul. Waclawa Sieroszewskiego 34, 24-100, Poland

Departments

-
Cardiology
cardiology department
Dermatology
Gastroenterology
General Medicine
KO-MED Centra Kliniczne Lublin II
KO-MED Centra Kliniczne Puławy
Ko-Med Centra Kliniczne Sp. z o.o. Staszów
KO-MED Centra Kliniczne Staszów
N/A
NA
Outpatient clinic
Site name: VELOCITY Zamość
Velocity Lublin

Clinical trials at this site (15)

Search interface

VB10.16 Plus Pembrolizumab in First Line r/m HNSCC Recruiting

2022-503055-26-00 Unresectable recurrent or metastatic HPV16 (Human Papil 9 2023-10-30
Study to Evaluate Plozasiran in Adults with Hypertriglyceridemia (MUIR-3 Study) Ended

2023-509302-30-00 Hypertriglyceridemia 5 2024-11-04
Randomised, placebo-controlled Phase II proof of concept study of efficacy and safety of a novel rifamycin SV in situ gelling rectal solutio… Ended

2023-506917-23-00 patients with mild to moderate left-sided ulcerative co 4 2024-04-19
A Phase 3/3b, Randomized, Observer-blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Fluad and Fluad … Ended

2022-503004-24-00 Influenza virus 5 2023-10-20
An open study for participants who have been on darolutamide treatment in any other Bayer study Ended

2022-502084-38-00 Cancer 5 2020-10-16
A Phase 2 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of ARO-APOC3 in Adults with Dyslipidemia Ended

2024-511331-96-00 Mixed Dyslipidemia 4 2024-07-04
A study to evaluate SAR441566 efficacy and safety in adults with rheumatoid arthritis Ended

2023-503910-60-00 Rheumatoid arthritis 4 2024-03-05
A study to investigate efficacy and safety of OG-6219 twice a day in 3 dose levels compared with Placebo in participants aged 18 to 49 with … Ended

2022-501310-57-00 Endometriosis related pain 4 2024-02-05
A Phase 3 Randomized Double-blind Controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of ExPEC9V and High-dose Quadr… Ended

2023-504168-40-00 Prevention of invasive extraintestinal pathogenic Esche 5 2023-11-06
A Phase III, open-label, randomized, controlled, multi-country study to evaluate the immune response, safety, and reactogenicity of respirat… Ended

2022-501988-40-00 RSV-associated (subtypes A and B) disease in adults age 5 2023-08-17
Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Ended

2024-512554-15-00 COVID-19 5 2023-06-21
An efficacy and safety study of HRO350 in patients with mild-to-moderate psoriasis (the ‘HeROPA’ study) Ended

2022-501850-12-00 Psoriasis 4 2023-03-15
A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis… Ended

2023-503794-38-00 Prevention of stroke or systemic embolism in atrial fib 5 2022-11-24
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended

2023-503673-38-00 Adults at high risk of cardiovascular events without pr 5 2019-05-24
A Phase 2a multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Burfiralimab (hzVSF-v13)… Ended

2023-507944-35-00 rheumatoid arthritis 4